UNSPSC 51111633: Edatrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C22H25N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JT4X6Z1HRR, chemically known as n-(p-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-l-glutamic acid but generally known as edatrexate, which bears US NIH Compound Identifier 54586. European Medicines Agency schedules Edatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06454MIG.

UNSPSC 51111633 Edatrexate, a Commodity code, classifies pharmaceutical procurement for a specific generic drug used in cancer treatment and autoimmune disorders. State and local governments procure edatrexate primarily through health and human services agencies managing pharmacy benefit programs for Medicaid, employee health plans, and other state-administered benefits. The code encompasses the supply chain activities around sourcing, contracting, and fulfillment of this specific medication — including direct procurement from manufacturers, negotiations with pharmacy benefit managers and wholesalers, and integration into state pharmacy formularies. Health and human services commissions and state pharmacy programs are the primary issuing bodies under this code, along with state employee health plan administrators and Medicaid agencies that manage prescription drug benefits across eligible populations.

The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI represents exploratory procurement activity designed to inform future strategy around direct contracting between the state and pharmaceutical manufacturers, outside traditional pharmacy benefit manager and group purchasing organization channels. The state is gathering intelligence on vendors' capacity to negotiate net pricing models, implement value-based agreements, and fulfill volume requirements across self-insured employee health plans and state agencies. Texas represents the primary recent activity under this code; no other state or local opportunities appear in the current record. This RFI signals state-level interest in restructuring pharmacy procurement channels for specific drugs like edatrexate, but no formal solicitation, award timeline, or contract value has been announced yet.